WFRF:(Elmér Eskil)
Sökning: WFRF:(Elmér Eskil) > Cyclosporine before...
- 10 av 117
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 05725naa a2200901 4500 | |
| 001 | oai:lup.lub.lu.se:1ed1e498-272a-41a1-9bd1-af6fddd4a7ae | |
| 003 | SwePub | |
| 008 | 160401s2015 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://lup.lub.lu.se/record/80774862 URI |
| 024 | 7 | a https://doi.org/10.1056/NEJMoa15054892 DOI |
| 040 | a (SwePub)lu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a art2 swepub-publicationtype |
| 072 | 7 | a ref2 swepub-contenttype |
| 100 | 1 | a Cung, T. -T.4 aut |
| 245 | 1 0 | a Cyclosporine before PCI in Patients with Acute Myocardial Infarction |
| 264 | 1 | c 2015 |
| 520 | a BACKGROUND Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval, 0.78 to 1.39; P = 0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.) | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
| 700 | 1 | a Morel, O.4 aut |
| 700 | 1 | a Cayla, G.4 aut |
| 700 | 1 | a Rioufol, G.4 aut |
| 700 | 1 | a Garcia-Dorado, D.4 aut |
| 700 | 1 | a Angoulvant, D.4 aut |
| 700 | 1 | a Bonnefoy-Cudraz, E.4 aut |
| 700 | 1 | a Guerin, P.4 aut |
| 700 | 1 | a Elbaz, M.4 aut |
| 700 | 1 | a Delarche, N.4 aut |
| 700 | 1 | a Coste, P.4 aut |
| 700 | 1 | a Vanzetto, G.4 aut |
| 700 | 1 | a Metge, M.4 aut |
| 700 | 1 | a Aupetit, J. -F.4 aut |
| 700 | 1 | a Jouve, B.4 aut |
| 700 | 1 | a Motreff, P.4 aut |
| 700 | 1 | a Tron, C.4 aut |
| 700 | 1 | a Labeque, J. -N.4 aut |
| 700 | 1 | a Steg, P. G.4 aut |
| 700 | 1 | a Cottin, Y.4 aut |
| 700 | 1 | a Range, G.4 aut |
| 700 | 1 | a Clerc, J.4 aut |
| 700 | 1 | a Claeys, M. J.4 aut |
| 700 | 1 | a Coussement, P.4 aut |
| 700 | 1 | a Prunier, F.4 aut |
| 700 | 1 | a Moulin, F.4 aut |
| 700 | 1 | a Roth, O.4 aut |
| 700 | 1 | a Belle, L.4 aut |
| 700 | 1 | a Dubois, P.4 aut |
| 700 | 1 | a Barragan, P.4 aut |
| 700 | 1 | a Gilard, M.4 aut |
| 700 | 1 | a Piot, C.4 aut |
| 700 | 1 | a Colin, P.4 aut |
| 700 | 1 | a De Poli, F.4 aut |
| 700 | 1 | a Morice, M. -C.4 aut |
| 700 | 1 | a Ider, O.4 aut |
| 700 | 1 | a Dubois-Rande, J. -L.4 aut |
| 700 | 1 | a Unterseeh, T.4 aut |
| 700 | 1 | a Le Breton, H.4 aut |
| 700 | 1 | a Beard, T.4 aut |
| 700 | 1 | a Blanchard, D.4 aut |
| 700 | 1 | a Grollier, G.4 aut |
| 700 | 1 | a Malquarti, V.4 aut |
| 700 | 1 | a Staat, P.4 aut |
| 700 | 1 | a Sudre, A.4 aut |
| 700 | 1 | a Elmer, Eskilu Lund University,Lunds universitet,Klinisk neurofysiologi,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Mitokondriell Medicin,Forskargrupper vid Lunds universitet,Clinical Neurophysiology,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Mitochondrial Medicine,Lund University Research Groups4 aut0 (Swepub:lu)expb-eel |
| 700 | 1 | a Hansson, Magnusu Lund University,Lunds universitet,Klinisk fysiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Mitokondriell Medicin,Forskargrupper vid Lunds universitet,Clinical Physiology (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Mitochondrial Medicine,Lund University Research Groups4 aut0 (Swepub:lu)expb-mha |
| 700 | 1 | a Bergerot, C.4 aut |
| 700 | 1 | a Boussaha, I.4 aut |
| 700 | 1 | a Jossan, C.4 aut |
| 700 | 1 | a Derumeaux, G.4 aut |
| 700 | 1 | a Mewton, N.4 aut |
| 700 | 1 | a Ovize, M.4 aut |
| 710 | 2 | a Klinisk neurofysiologib Sektion IV4 org |
| 773 | 0 | t New England Journal of Medicineg 373:11, s. 1021-1031q 373:11<1021-1031x 0028-4793 |
| 856 | 4 | u http://dx.doi.org/10.1056/NEJMoa1505489y FULLTEXT |
| 856 | 4 8 | u https://lup.lub.lu.se/record/8077486 |
| 856 | 4 8 | u https://doi.org/10.1056/NEJMoa1505489 |
Hitta via bibliotek
- New England Journal of Medicine (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 10 av 117
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Cung, T. -T.
- Morel, O.
- Cayla, G.
- Rioufol, G.
- Garcia-Dorado, D ...
- Angoulvant, D.
- visa fler...
- Bonnefoy-Cudraz, ...
- Guerin, P.
- Elbaz, M.
- Delarche, N.
- Coste, P.
- Vanzetto, G.
- Metge, M.
- Aupetit, J. -F.
- Jouve, B.
- Motreff, P.
- Tron, C.
- Labeque, J. -N.
- Steg, P. G.
- Cottin, Y.
- Range, G.
- Clerc, J.
- Claeys, M. J.
- Coussement, P.
- Prunier, F.
- Moulin, F.
- Roth, O.
- Belle, L.
- Dubois, P.
- Barragan, P.
- Gilard, M.
- Piot, C.
- Colin, P.
- De Poli, F.
- Morice, M. -C.
- Ider, O.
- Dubois-Rande, J. ...
- Unterseeh, T.
- Le Breton, H.
- Beard, T.
- Blanchard, D.
- Grollier, G.
- Malquarti, V.
- Staat, P.
- Sudre, A.
- Elmer, Eskil
- Hansson, Magnus
- Bergerot, C.
- Boussaha, I.
- Jossan, C.
- Derumeaux, G.
- Mewton, N.
- Ovize, M.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- New England Jour ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
